NCT06897488View on ClinicalTrials.gov

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions

Breast Cancer

Interventions

RADIATION

Adjuvant Radiotherapy

Participants will receive treatment following Lumpectomy

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT06897488 - EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | Biotech Hunter | Biotech Hunter